Company Overview and News
The business combination of Legacy Reserves LP (LGCY) with Legacy Reserves GP, LLC,. (the Partnership) has closed today, September 20, 2018. As a result, the Units Representing Limited Partner Interests (LGCY) will undergo a name, CUSIP number and issue type change effective on Friday, September 21, 2018. There is no change to the symbol. The Series A Preferred (LGCYP) & Series B Preferred (LGCYO) will be suspended from trading effective September 21, 2018.
LGCYP LGCYO LGCY
2018-09-04 seekingalpha - 1
The 18 remaining companies in the Bottom of the Barrel Club recently reported 2Q results that were largely underwhelming overall.
ECR CRC APC PIO LGCYP LGCYO CRK DVN EPE SCAZP PIONF AXAS XTO MCEP ACTPF AREX MHRC EGC RXNRP REXXQ JNEEP SNZYP AST SN JGPK TALO BRMR SRCI MAGH JONE EOG DNR REXX BBG CHK CVX SGY LGCY HPR BRY AEUA
2018-08-18 seekingalpha - 3
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
FOCS PDD LGCYP LGCYO QEP TJX EL AVGO ABBV FTNT KLXI CORR ESES SDPI TENB LNR RRS WPX FSBW ESTE NPTN ERF BABA SDCJF PAY MSFT GPS MPOYQ HRS FL MLM BLCN MOS SEA CLPS LB CLB ROSEU DBX CF CRDAF KSS CRDAD CI SSI JAG ROSE SNDE DAVA SJM UNT HUM EOG BHI RGRYY MU LGCY SBUX MNK WRD LOW JKS TOL LONE ERF CLB FTK AMAT CRD KEG KEGX SOXX STT FSWB WLL AQST SM LBRT BV LLEX ADIL NBR RGRLF CMG RRC INTU HIMX BJRI EDUC BE MPO ABBV BA ESRX ECR JG NDLS WPXP MTB RRL VMW ALRM LQDA RMBS ECA CANG ICD OPRA IBM WISA CDEV JGPK LYB COG ECA SPDI SBOW PHX TGT NTR BRY HPQ URBN TELL
2018-07-30 seekingalpha - 6
The first half of 2018 was marked by plenty of news and significant volatility from BOTB Club stocks.
CRC LGCYP LGCYO LNGG CHKVP CRK CHKVZ SQTI EXXIQ KMI RXNRP EXIXQ SNZYP KMR AST CVB SN NBL TALO SRCI EEXXQ RRS JONE EXXI RGRLF RRC DNR CHK SGY TTEN LINE ECR UPL REN PVA EPE RRL SCAZP CHKDH XCOOQ ACTPF CHKDG VNGE AREX CHKDJ CHKDP REXXQ JNEEP XCOO LINEQ CKRGZ EVEP PVAYQ CHKWZ XCO RGRYY REXX CHK.WI PVAC LGCY UPLMQ BRY KMRFZ
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET